cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Stockal+Disclaimer.pdf
9 own
23 watching
Current Price
$0.89
$-0.02
(-2.09%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
81.31M
52-Week High
52-Week High
1.57000
52-Week Low
52-Week Low
0.88000
Average Volume
Average Volume
0.24M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization81.31M
icon52-Week High1.57000
icon52-Week Low0.88000
iconAverage Volume0.24M
iconDividend Yield--
iconP/E Ratio--
What does the Stockal+Disclaimer.pdf do?
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company s approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Globe Newswire
1 year ago
- Continued Execution and Progress Towards Commercial Approval of Dordaviprone (ONC201) with Global Launch of Phase 3 ACTION Study Confirmed Response in Non-H3 K27M Recurrent Glioblastoma Patient During ONC206 Dose Escalation Strong Balance Sheet with $266 Million in Cash at Year-End and No Debt ...
Globe Newswire
1 year ago
DURHAM, N.C., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Chimerix(NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer, will present a ...
Business Wire
1 year ago
Rubric Capital Management LP (Rubric), an investment adviser whose managed funds and accounts collectively own approximately 8.5% of the common stock of Chimerix, Inc. (Chimerix or the Company) (NASDAQ: CMRX), today sent a letter to Chimerixs Board of Directors (the Board). In its letter, Rubric...
Globe Newswire
1 year ago
- Initial Procurement of 319,000 Treatment Courses for $115M with Additional Procurements at BARDAs Discretion Over 10 Years - Emergent BioSolutions, Inc. Payment Increases to $238M Upfront and $136.5M in Potential Milestones - DURHAM, N.C., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Chimerix(NASDAQ:CMRX), a...
PR Newswire
1 year ago
Demand for Comprehensive Cleaning Services Grow Post-Pandemic Demand for Comprehensive Cleaning Services Grow Post-Pandemic PR Newswire NEW YORK, Aug. 26, 2022 FinancialBuzz.com News Commentary NEW YORK, Aug. 26, 2022 /PRNewswire/ -- Due to the growing implementation of AI and automation in...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$0.89
$-0.02
(-2.09%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Instil Bio, Inc.
Instil Bio, Inc.
$10.40
$-0.31 (-2.89 %)
DBV Technologies S.A.
DBV Technologies S.A.
$0.69
$-0.00 (-0.23 %)
PROQR THERAPEUTICS NV
PROQR THERAPEUTICS NV
$1.96
$-0.05 (-2.49 %)
Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc.
$2.43
$-0.09 (-3.57 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Instil Bio, Inc.
Instil Bio, Inc.
$10.40
$-0.31 (-2.89 %)
DBV Technologies S.A.
DBV Technologies S.A.
$0.69
$-0.00 (-0.23 %)
PROQR THERAPEUTICS NV
PROQR THERAPEUTICS NV
$1.96
$-0.05 (-2.49 %)
Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc.
$2.43
$-0.09 (-3.57 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00